Sarepta pulls plug on Duchenne exon-skipping drug
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Newsletters and Deep Dive digital magazine
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
The Molecular Glue Drug Development Summit is back in January, 2025!
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
RNAi-Based Therapeutics Returns!
Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part
Editor's Picks
Newsletters and Deep Dive
digital magazine